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Cancer cells that leave the primary tumor can seed
metastases in distant organs, and it is thought that
this is a unidirectional process. Here we show that
circulating tumor cells (CTCs) can also colonize their
tumors of origin, in a process that we call ‘‘tumor
self-seeding.’’ Self-seeding of breast cancer, colon
cancer, and melanoma tumors in mice is preferen-
tially mediated by aggressive CTCs, including those
with bone, lung, or brain-metastatic tropism. We
find that the tumor-derived cytokines IL-6 and IL-8
act as CTC attractants whereas MMP1/collagenase-1
and the actin cytoskeleton component fascin-1 are
mediators of CTC infiltration into mammary tumors.
We show that self-seeding can accelerate tumor
growth, angiogenesis, and stromal recruitment
through seed-derived factors including the chemo-
kine CXCL1. Tumor self-seeding could explain the
relationships between anaplasia, tumor size, vascu-
larity and prognosis, and local recurrence seeded
by disseminated cells following ostensibly complete
tumor excision.INTRODUCTION
Cancer progression is commonly segregated into processes of
primary tumor growth and secondary metastasis. In this conven-
tional model, the high cell density and rapid growth rate of
primary tumors are attributed to an ability of cancer cells to
sustain unlimited proliferation and to favorably influence their
microenvironment. In contrast, metastasis is thought to depend
on cancer cell dissemination and adaptation to distant organs
(Chiang and Massague´, 2008; Langley and Fidler, 2007; Scheel
et al., 2007). Shedding of tumor cells into the circulation may
occur in large numbers and from early stages of tumor formation
(Husemann et al., 2008; Pantel and Brakenhoff, 2004; Stoecklein
et al., 2008). Yet overt metastasis is achieved only by a minority
of these dispersed cells. Tight vascular wall barriers, unfavorable
conditions for survival in distant organs, and a rate-limitingCacquisition of organ colonization functions are just some of the
impediments to the formation of distant metastasis (Nguyen
et al., 2009). However, these impediments may be less stringent
as regards the ability of CTCs to reinfiltrate their tumors of origin.
The neovasculature of tumors is typically leaky (Carmeliet and
Jain, 2000; Rafii et al., 2003), a feature that would facilitate not
only the passage of tumor cells into the circulation but also their
entry from the circulation back into the tumor. CTCs would likely
need no further adaptation to thrive in the microenvironment of
their source tumor. Based on these theoretical considerations,
we have postulated that CTCs may reinfiltrate an established
tumor, enriching it with aggressive cells that have withstood
a period of dissemination. This process, which we refer to as
‘‘tumor self-seeding,’’ could have consequences for tumor
growth and the breeding of metastatic cell progenies (Norton
and Massague, 2006).
In the present studieswe sought experimental evidence for the
existence, the features, the mediators, and the potential conse-
quences of tumor self-seeding. Using human breast, colon, and
melanoma cancer cells, we investigated in mice the ability of
malignant cells to seed a tumor from the circulation. The results
led us to investigate whether metastatic cells have a superior
ability to seed an established tumor, and whether tumor self-
seeding depends on attraction signals from the tumor mass
and infiltrative functions in the circulating seeds. Our results
uncovered various mediators of such attraction and infiltration
functions, including factors whose expression in primary tumors
is associated with relapse in patients. These insights dissect
tumor self-seeding into steps of CTC attraction and tumor infil-
tration and highlight the implications of tumor self-seeding for
cancer biology and clinical oncology.RESULTS
Seeding of Established Tumors by CTCs
To investigate whether cancer cells that are shed into the circu-
lation can reinfiltrate a primary tumor mass, we first used MDA-
MB-231 (MDA231 for brevity), a breast cancer cell line from
which metastatic subpopulations were previously isolated and
characterized (Bos et al., 2009; Kang et al., 2003; Minn et al.,
2005a). The lung-metastatic derivative line MDA231-LM2 (Minn
et al., 2005a) was transducedwith aGFP-luciferase fusion vectorell 139, 1315–1326, December 24, 2009 ª2009 Elsevier Inc. 1315
Figure 1. Seeding of Established Tumors by CTCs
(A) A diagram of contralateral seeding experiment. Unlabeled and GFP/luciferase-expressing breast cancer cells were injected into contralateral No. 2 mammary
glands as a ‘‘recipient tumor’’ and a ‘‘donor tumor,’’ respectively.
(B) BLI of recipient tumors extracted frommice bearing the indicated GFP/luciferase-expressing donor tumors. Color-range bars: photon flux. LM2: a lung-meta-
static derivative of MDA231. MCF7-BoM2: a bone-metastatic derivative of MCF7. CN34-BrM2: a brain-metastatic derivative of pleural effusion CN34. PyMT:
cells derived from mammary tumors developed in MMTV-PyMT transgenic mice.
(C) BLI of tumor-free and tumor-bearing mammary glands from mice bearing GFP/luciferase-expressing donor tumors. n = 9–18. Error bars represent SEM.
(D) Frozen sections of seededMDA231-LM2 tumorswere visualized by fluorescencemicroscopy. An entire tumor section and a higher-magnification image (310)
of a selected field are shown.
(E) A contralateral seeding experiment was performed with RFP- and GFP-expressing MDA231-LM2 cells. Frozen sections from RFP-labeled tumors were
visualized under confocal microscopy at 320.
(F) A diagram to test mammary tumor seeding from lung metastases. GFP/luciferase-expressing MDA231-LM2 cells were injected intravenously. Once lung
metastases were established, unlabeled MDA231 cells were injected into a mammary gland No. 2.
(G) Left: burden of CTCs derived from lung metastases in mice described in (F). Relative levels of CTC were plotted against the luminescent signals of recipient
tumors. Right: BLI of three representative recipient tumors (i, ii, and iii) identified in the graph.and inoculated into one mammary gland in mice to form
a ‘‘donor’’ tumormass. UnlabeledMDA231-LM2 cells were inoc-
ulated into a contralateral mammary gland to form a ‘‘recipient’’
mass of the same tumor (Figure 1A). After 60 days, the recipient
tumors were excised and examined for the presence of seeding
cells by means of ex vivo bioluminescence imaging (BLI).
A majority (85%) of the recipient tumors showed extensive seed-
ing by MDA231-LM2 cells (Figure 1B and Table 1). Tumors
formed by the more indolent MDA231 parental population were
as effective as MDA231-LM2 tumors at capturing seed cells
(Figure 1B and Table 1). No seeding was observed in mock-inoc-
ulated mammary glands within the same time period (Figure 1C).
Fluorescence microscopy analysis of MDA231 recipient
tumors confirmed the presence of numerous GFP+ MDA231-
LM2 seeding cells as distinct patches typically encompassing
less than a quarter of a tumor section (Figure 1D and data not
shown). When recipient tumors were generated using red-
fluorescent protein (RFP)-labeled cells, the infiltrating GFP+ cells1316 Cell 139, 1315–1326, December 24, 2009 ª2009 Elsevier Inc.were observed intermingling with resident RFP+ cancer cells and
with unlabeled areas of presumptive tumor stroma (Figure 1E).
Quantitative RT-PCR analysis of firefly-luciferase mRNA level
in seeded recipient tumors revealed that seeder cells accounted
for 5%–30% of the recipient tumor mass (data not shown).
To establish the generality of this seeding phenomenon, we
performed similar experiments with different cancer cell lines.
Recipient mammary tumors became seededwith high frequency
(53% to 100% of mice) by donor tumors that were formed with
bone-metastatic (MCF7-BoM2), lung-metastatic (MDA231-
LM2), or brain-metastatic (CN34-BrM2) cells from different sub-
types of breast cancer (basal, estrogen receptor-negative
MDA231 cells versus luminal, estrogen receptor-positive MCF7
cells) or patient-derived malignant cell cultures (CN34 cells)
(Figure 1B and Table 1). Seeding of a recipient tumor by its own
aggressive progeny was also observed between subcutaneous
tumors formed by the human colon carcinoma line SW620 and
its lung-metastatic derivative SW620-LM1, and between the
Table 1. Tumor-Seeding Activity of Various Carcinoma and Melanoma Cell Lines
Cancer Relationship Species Donor Tumor Recipient Tumor Site Seeding (%)
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Breast
Homotypic
Homotypic
Homotypic
Homotypic
Homotypic
Human
Human
MDA231-LM2
MDA231-LM2
MDA231-LM2
MDA231
MFP
MFP
11/13 (85)
39/47 (83)
Mouse
Mouse
Mouse
4T1
4T1
PyMT
4T1
67NR
PyMT endogenous
MFP
MFP
Breast
3/5 (60)
11/11 (100)
8/11 (73)
Heterotypic
Heterotypic
Heterotypic
Human
Human
Human
CN34-BrM2
MCF7-BoM2
MDA231-LM2
MDA231
MDA231
MCF7
MFP
MFP
MFP
10/19 (53)
6/7 (86)
7/7 (100)
Melanoma Homotypic Human A375-BoM2 A375 SubQ 8/11 (73)
Colon Homotypic Human SW620-LM1 SW620 SubQ 7/9 (77)
The table indicates the type of cancer, the relationship, species, and name of the cell lines used as donor and recipient pairs, the tumor site (MFP:
mammary fat pad, SubQ: subcutaneous), and the fraction of tumors that showed seeding as determined by BLI. MDA231-LM2, a lung-metastatic
derivative of MDA231; MCF7-BoM2, a bone-metastatic derivative of MCF7; CN34-BrM2, a brain-metastatic derivative of pleural effusion CN34;
SW620-LM1, a lung-metastatic derivative of SW620; A375-BoM2, a bone-metastatic derivative of A375. PyMT: cells derived from a mammary tumor
developed in MMTV-PyMT transgenic mice.human melanoma line A375 and its bone-metastatic derivative
A375-BoM2 (Table 1). These experiments with human cell lines
required the use of immunodeficient mice. However, seeding
was also observed in immunocompetent mice using the synge-
neic cell lines 4T1 and 67NR (Table 1). Derived from a sponta-
neous mousemammary tumor, 4T1 is highly metastatic to lungs,
liver, bones, and brain whereas 67NR is poorlymetastatic (Aslak-
son and Miller, 1992). Moreover, endogenous mammary tumors
driven by the polyoma middle T oncogene (PyMT) in mice were
efficiently seeded by PyMT tumor-derived cells placed in the
circulation (Figure 1B; Table 1).
To determine if mammary tumors may be seeded with cells
shed from metastatic lesions, we generated lung tumor colonies
by tail-vein inoculation of labeled MDA231-LM2 cells and then
implanted unlabeled MDA231 mammary tumors in the same
mice (Figure 1F). Seeding of these mammary tumors by lung
metastasis-derived cells was observed in 10/11 (91%) mice
(Figure 1G). The extent of seeding was proportional to the level
of donor cells in the circulation (Figure 1G). Collectively, these
results indicate that aggressive carcinoma and melanoma cells
shed into the circulation can avidly seed an established tumor
mass.
Preferential Tumor Seeding by Metastatic
Cell Progenies
We compared the ability of metastatic derivatives from SW620,
A375, and MDA231 with their corresponding parental lines to
act as donor tumors. In contralateral homotypic tumor seeding
assays, the metastatic derivatives showed an 8- to 35-fold
higher seeding ability than their parental counterparts, as deter-
mined by BLI of homotypic recipient tumors (Figure 2A). Next we
carried out in vivo selection experiments to isolate, from the
parental MDA231 and A375 cell lines, the cells that most actively
seed a tumormass from the circulation.We inoculated contralat-
eral mammary glands (MDA231) or contralateral flanks of mice
(A375) with unlabeled (recipient) or GFP/luciferase-labeled
(donor) cells, respectively (Figure 2B). Seeding of recipient
tumors was detectable by BLI within 50 days of the inoculation.
The seeded tumors were excised, dissociated, and placed inCculture, and the GFP-positive seeder cell populations (MDA231-
S1a, MDA231-S1b, and A375-S1) were obtained from these
cultures by fluorescence-activated cell sorting (FACS). The
tumor seeding ability of MDA231-S1a and MDA231-S1b as
contralateral donor tumors was >100-fold higher than that of
parental MDA231 (Figure 2C). The seeding ability of MDA231-
S1a and A375-S1 from the circulation was 6-fold higher than
that of the parental populations (Figure 2D). The S1 populations
additionally showed an increased ability to pass across an endo-
thelial cell layer in trans-well migration assays (Figure S1 avail-
able online).
We choseMDA231 for further analysis because themetastatic
composition of this cell line has been extensively characterized.
MDA231 was derived from the pleural fluid of a breast cancer
patient with advanced metastatic disease, and it contains
minority subpopulations that are highly metastatic to either the
bones, the lungs, or the brain (Bos et al., 2009; Kang et al.,
2003; Minn et al., 2005a). These subpopulations may represent
the disseminated descendants of different metastatic lesions in
the source patient and are characterized by a differential expres-
sion of distinct gene sets. Several of these genes act as media-
tors of organ-specific metastasis in experimental systems and
are associated with organ-specific relapse in independent
cohorts of breast cancer patients (Bos et al., 2009; Kang et al.,
2003; Minn et al., 2005a, 2005b).
A comparison of transcriptional profiles uncovered 72 genes
(78 probe sets) whose mRNA level was at least 3-fold higher in
the MDA231-S1a and -S1b cells than in parental MDA231 (Table
S1). Interestingly, many of these are genes whose expression is
characteristic of bone, lung, and/or brain-metastatic cell popula-
tions (Table S1) (Bos et al., 2009; Kang et al., 2003; Minn et al.,
2005a). The antiapoptotic gene BCL2A1 was also highly ex-
pressed in S1 cells (Table S1). Furthermore, the MDA231-S1a
and -S1b transcriptomes were significantly enriched for the
expression of bone metastasis (BoMS), lung metastasis (LMS),
and brain metastasis (BrMS) gene expression classifiers (Fig-
ure 2E). These signatures were previously derived from human
breast cancer cells that are selectively metastatic to one of these
organs in mouse models and in patients (Bos et al., 2009; Kangell 139, 1315–1326, December 24, 2009 ª2009 Elsevier Inc. 1317
Figure 2. Preferential Tumor Seeding by Metastatic Cell Progenies
(A) Comparison of seeding activity of highly and poorly metastatic cells. Contralateral seeding experiments were performed with the GFP/luciferase-expressing
parental cancer cell lines, or with their lung-metastatic (SW620-LM1, MDA231-LM2) or bone-metastatic derivatives (A375-BoM2). Relative luminescent signals
are plotted.
(B) A schematic diagram of isolation of seeder cell populations. For details, see Experimental Procedures.
(C) Comparative tumor-seeding ability of in vivo-selected seeder cells (MDA231-S1a and S1b) and parental MDA231 cells in contralateral seeding experiments as
described in Figure 1A. n = 6–8.
(D) Comparative tumor-seeding ability between parental and in vivo-selected seeder cells (MDA231-S1 and A375-S1) from the circulation as described in
Figure 3A. n = 8–10.
(E) The gene expression profiles of parental MDA231, various metastatic derivatives, and the seeder lines S1a and S1b were scored with gene expression
classifiers for metastasis to lung (LMS), bone (BoMS), or brain (BrMS). Raw scores were scaled between 0 and 100.
(F) Left: Parental or MDA231-S1a cells were inoculated intravenously into mice. Lung colonization was measured by BLI and quantified. n = 6–7. Right:
representative histological staining (H&E) of lung sections from the experiment on the left.
(G and H) Cells were inoculated into the cardiac left ventricle. Bone colonization was measured by BLI and quantified; n = 12. Brains were extracted and
colonization was measured by BLI; n = 5–7.
Error bars in all cases represent SEM and p values were based on two-tailed Mann-Whitney test; for details see Experimental Procedures.et al., 2003; Minn et al., 2005a, 2005b). Indeed, when compared
to parental MDA231 in metastasis assays in mice, the MDA231-
S1a cells demonstrated a higher ability to colonize the lungs (Fig-
ure 2F), the bones (Figure 2G), and the brain (Figure 2H) from the
circulation. Collectively, these results suggest that tumor self-
seeding preferentially involves metastatic cancer cell progenies
irrespective of their organ tropisms.
Tumor Attraction and Infiltration Functions
To define the basic functions required for tumor seeding by
CTCs, we inoculated LacZ/GFP/luciferase-expressing MDA231
cells (either parental or LM2) into the arterial circulation (via the
left cardiac ventricle) of mice bearing unlabeled MDA231
mammary tumors (Figure 3A). This experimental protocol obvi-
ates possible differences in donor tumor growth rate or in donor
tumor-derived systemic signals (McAllister et al., 2008) that
might confound the interpretation of our results. The inoculated1318 Cell 139, 1315–1326, December 24, 2009 ª2009 Elsevier Inc.cells were rapidly distributed throughout the body (Figure 3B,
day 0) and became extensively cleared within a few days
except for cells that infiltrated the mammary tumors (Figure 3B,
day 7 and beyond). These cells readily seeded the established
mammary tumors but not the intact or mock-inoculated
mammary glands (Figure 3B, day 42). Furthermore, the highly
metastatic MDA231-LM2 cells were more effective at seeding
the recipient tumors from the circulation than were the parental
MDA231 cells (Figure 3C). This effect was already apparent
within 10 days after inoculation (Figure 3D), before a marked
outgrowth of the seeding cells took place within the recipient
tumor mass. In similar experiments, the metastatic derivative
A375-BoM2 seeded subcutaneous A375 melanoma tumors
from the circulation more effectively than did the parental A375
cells (Figure 3D). These results suggested that tumor seeding
by CTCs involves two distinct functions, namely, an ability of
tumors to attract their own circulating progeny and an ability of
Figure 3. Tumor Attraction and Infiltration Functions
(A) Unlabeled MDA231 cells were injected into a mammary gland No. 2. When tumors became palpable, LacZ/GFP/luciferase-expressing MDA231-LM2 cells
were introduced into the circulation by intracardiac injection.
(B) BLI of mice with seeded and unseeded tumors. Arrow, recipient tumor.
(C) Comparative tumor-seeding ability of MDA231 and MDA231-LM2 cells from the circulation. Luminescent signals from recipient tumors at the indicated time
points are shown.
(D) Luminescent signals of recipient tumors from mice injected with indicated cell lines were quantified 10 (MDA-231) and 5 (A375) days after injection. n = 6–10.
(E) A diagram summarizing two functions involved in tumor self-seeding.
Error bars in all cases represent SEM and p values were based on two-tailed Mann-Whitney test.CTCs to infiltrate tumors in response to this attraction (Fig-
ure 3E).
To gain further insight into these attraction and infiltration
functions, we performed a trans-endothelial migration assay in
which tumor cell-conditioned media were placed in the bottom
well of the chamber (Figure 4A). Media conditioned by MDA231
breast carcinoma or A375 melanoma cells were several-fold
more active at stimulating the trans-endotheilal migration of
MDA231-LM2 cells than were media conditioned by MCF10A
cells, a human breast epithelial cell line derived from untrans-
formed tissue (Figure 4B). Similarly, A375-BoM2melanoma cells
migrated throughendothelial cell layersmoreactively in response
to these cancer cell-conditioned media than to media condi-
tioned by HaCat cells (Figure 4B), a human keratinocyte cell line
representing the most abundant cell type in skin epidermis.
Media fromMDA231 andMDA231-LM2 cultureswere equivalent
as a source of attraction in these experiments (Figure 4C), which
is consistent with the equivalent ability of these two cell lines to
act as recipient tumors in self-seeding assays (refer to Figure 1B
and Table 1).
MDA231-LM2 cells aremore active atmigrating through endo-
thelial cell layers compared to parental MDA231 cells (Gupta
et al., 2007). Conditioned media from either MDA231-LM2 orCMDA231 cells further stimulated the trans-endothelial migration
of MDA231-LM2 cells (Figure 4C). Parental MDA231 cells
showed low trans-endothelial migration activity even in the pres-
ence of media conditioned by tumor cells (Figure 4C). Similarly,
the migration of A375-BoM2 cells through endothelial layers
was several-fold more efficient than that of the parental A375
cells in the presence of conditioned media from A375 or A375-
BoM2 (Figure 4C). These results demonstrated that cancer cells
release signals that attract their progeny across endothelial
layers. In addition, these results suggest that aggressive cancer
cells are superior to their more indolent counterparts in their
ability to migrate in response to these signals.
Tumor-Derived Mediators of Cancer Cell Attraction
To identify candidate tumor-derived attractants for CTCs, we
compared the secreted levels of 180 cytokines in conditioned
media. This analysis uncovered several cytokines whose
production was higher (IL-6, IL-8, oncostatin M, and vascular
endothelial growth factor [VEGF]) or lower (CCL2) in MDA231
and its derivatives than in MCF10A cells (Figures 5A, S2A, and
S2B). IL-6 and IL-8 showed the sharpest increase. IL-8 was
also the most abundantly secreted cytokine in A375 melanoma
cells compared to the HaCat cells. IL-6 and IL-8 are regulatorsell 139, 1315–1326, December 24, 2009 ª2009 Elsevier Inc. 1319
Figure 4. Tumor-Derived Mediators of Cancer Cell Attraction
(A) Schematic diagram of the in vitro trans-endothelial migration assay. Condi-
tioned media were placed in the bottom well. Test cells were plated in the top
trans-well chamber. A confluent monolayer of human endothelial cells was
present as indicated. Quantification was performed as described in the Exper-
imental Procedures.
(B) Trans-endothelial migration of MDA231-LM2 and A375-BoM2 cells in the
presence of media conditioned by the indicated cell lines. n = 60–150.
(C) Trans-migration activity of tumor cells under indicated conditions was ex-
pressed as a fold difference relative to migration of parental MDA231 or A375
cells in the presence ofmedia from nontumorigenic cells (MCF10A conditioned
media for MDA231; HaCat conditioned media for A375). n = 40–70.
Error bars in all cases represent SEM and p values were based on two-tailed
Mann-Whitney test.of immune and inflammatory responses and have been impli-
cated in tumor progression (Hodge et al., 2005; Kishimoto,
2005). Focusing on these two cytokines, the addition of recombi-
nant IL-6 or IL-8 to media from the corresponding nontumori-
genic cells (MCF10A and HaCat, respectively) stimulated
the trans-well migration of MDA231-LM2, MDA231-S1a, and
A375-BoM2 cells (Figure 5B). These effects were maintained or
further increased in the presence of an endothelial cell layer
(Figure 5C). IL-8 had little effect on MDA231-LM2 migration1320 Cell 139, 1315–1326, December 24, 2009 ª2009 Elsevier Inc.(data not shown), but these cells lack IL-8 receptors (CXCR-1
and 2) (Helbig et al., 2003).
To determine the role of IL-6 on the attraction of MDA231
CTCs in vivo while averting the confounding effects of IL-6
on tumor vessels, we tested MDA231-S1a cells whose IL-6
receptor (IL6R) expression was inhibited with RNAi (Figure S3A).
The knockdown of IL6R expression significantly decreased the
self-seeding ability of seeder cells (Figure 5D). The knockdown
of IL6ST (gp130) (Figure S3A), a shared signal transducer for
IL-6 cytokine family members including oncostatin M, strongly
inhibited the seeding activity of MDA231-S1a (Figure 5D). Taken
together, these results suggest that tumor-derived IL-6 and
IL-8 can facilitate the self-seeding in these breast carcinoma
and melanoma models by functioning as chemoattractants for
circulating tumor cells.
Mediators of Cancer Cell Infiltration of Tumors
Theenriched expression of variousmetastasis-associated genes
in the MDA231-S1a and S1b populations indicated a preferential
seeding of tumors by their metastatic cell progenies (refer to
Figure 2E and Table S1). But this alone did not specifically link
these genes to the ability of CTCs to infiltrate a tumor mass. To
identify candidate mediators of this function, we searched this
list for proinvasive genes whose expression in primary breast
tumors has been previously associated with relapse in breast
cancer. These criteria were based on the rationale that expres-
sion of suchmediators in primary tumor cells would endow these
cells with a potential infiltrative advantage as they pass into the
circulation.
These criteria were fulfilled by three genes (Table S1), namely,
collagenase 1 (matrix metalloproteinase 1, MMP1), FASCIN 1
(FSCN1), and CXCL1. All three genes are implicated in invasion
and infiltration and, most importantly, their expression in breast
tumors is associatedwith priming of breast cancer cells for seed-
ing of the lungs (MMP1, FSCN1, and CXCL1) and the brain
(MMP1, FSCN1) (Bos et al., 2009; Minn et al., 2005a). These
are among the top-ranked genes by association with lung
relapse in the LMS signature in breast cancer patients (Minn
et al., 2005a). MMP1 has been implicated in tumor cell invasion,
vascular remodeling, and pulmonary extravasation (Egeblad and
Werb, 2002; Gupta et al., 2007). Fascin-1 is an actin crosslinking
protein that functions in the organization of cytoplasmic microfil-
ament bundles and dynamic, cortical cell protrusions including
filopodia, lamellipodia, and dendrites (Adams, 2004; Hashimoto
et al., 2005). Fascin-1 has been implicated in the migration and
invasiveness of malignant glioma and colorectal carcinoma cells
(Hwang et al., 2008; Vignjevic et al., 2007). CXCL1 is a powerful
mediator of leukocyte influx into sites of inflammation (Dhawan
and Richmond, 2002; Kobayashi, 2008) and also participates
in the recruitment of endothelial precursor cells for angiogenesis
(Hristov et al., 2007).
Using qRT-PCR, we confirmed that the expression level of
FSCN1, CXCL1, and MMP1 was 11-fold to >40-fold higher in
the S1a and S1b seeder populations than in parental MDA231
(Figure S3B). To investigate the role of these genes in tumor
seeding, we conducted trans-endothelial migration assays with
MDA231-S1a cells in which the expression of these genes was
inhibited with RNAi vectors (Figures S3C–S3E). Whereas the
Figure 5. Mediators of Tumor Infiltration by Cancer Cells
(A) Cytokine antibody arrays (Raybiotech) probed withMCF10A, MDA231, andMDA231-LM2 conditionedmedia. The positions of IL-6 and IL-8 are indicated. For
additional annotation see Figure S2.
(B) Relative trans-well migration activity (without endothelial cell layer) of the indicated cell lines, with or without IL-6 or IL-8. n = 89–110.
(C) Relative trans-endothelial migration activity of indicated cells with or without IL-6 or IL-8. n = 84–124.
(D) Relative seeding activity of MDA231-S1a cells expressing the indicated shRNA from the circulation. n = 5–10.
(E) Trans-endothelial migration activity of indicated cell lines. n = 30–45.
(F) Relative seeding activity of MDA231-S1a cells expressing indicated shRNA from the circulation. n = 5–8; error bars, maximum and minimum values.
(G) Lung colonization activity of MDA231-S1a cells expressing indicated shRNAs. n = 6–7.
Error bars in all cases represent SEM and p values were based on two-tailed Mann-Whitney test unless indicated otherwise.knockdown of MMP1 or CXCL1 singly had no effect on trans-
endothelial migration, the knockdown of FSCN1 expression
significantly decreased this activity (Figure 5E). The combined
knockdown of MMP1 and FSCN1 further decreased this migra-
tion, whereas the combined knockdown of CXCL1 and FSCN1
did not (Figure 5E). Correlating with these effects, the ability of
MDA231-S1a cells to infiltrate MDA231 mammary tumors from
the circulation was significantly diminished by FSCN1 knock-
down and was further decreased by a combined knockdown
of MMP1 and FSCN1 (Figure 5F). The knockdown of MMP1
(Gupta et al., 2007) or FSCN1 (Figure S3F) had no effect on
the growth of MDA231-LM2 cells as mammary tumors. The
combined knockdown of MMP1 and FSCN1 in MDA231-S1a
cells also inhibited the ability of these cells to colonize the lungs
of mice from the venous circulation (Figure 5G). These resultsCsuggest that FSCN1 and MMP1, two genes whose expression
in primary tumors is associated with distant relapse to lung
and brain in breast cancer patients (Bos et al., 2009; Minn
et al., 2005a), may also mediate the reinfiltration of mammary
tumors by CTCs.
Promotion of Tumor Growth and Stroma
Recruitment by Self-Seeding
Aggressive cancer cells may promote tumor growth through the
release of paracrine signals that enhance tumor angiogenesis
and the recruitment of a supportive stroma (Carmeliet, 2005;
Coussens and Werb, 2002; Joyce and Pollard, 2009; Tisty and
Coussens, 2006). To determine if the seeding of a tumor mass
by aggressive CTCs could affect the rate of tumor growth, we im-
planted MDA231 mammary tumors in mice and 10 days later weell 139, 1315–1326, December 24, 2009 ª2009 Elsevier Inc. 1321
Figure 6. Promotion of Tumor Growth and Stroma Recruitment by Self-Seeding
(A) Tumor volumes of MDA231-LM2-seeded and -unseeded tumors at the indicated time points. n = 13–14.
(B and C) b-galactosidase staining of a typical tumor seeded with LacZ+ MDA231-LM2 cells. An entire tumor section (B) and a340 magnification (C) are shown.
(D) CD31 staining of sections from unseeded and seeded tumors.
(E) CD45 staining of sections from unseeded and seeded tumors.
(F) Anti-neutrophil staining of sections from unseeded and seeded tumors.
(G) CD68 staining of sections from unseeded and seeded tumors.
(H) Seeding experiments from the circulation were performed with 4T1 in syngeneic mice and with A375-BoM2 cells. Recipient tumors were analyzed by FACS.
The percentage of stromal cells positively stained for the indicated markers are shown. p values were calculated based on two-tailed student’s t test.
(I) Seeding experiments from the circulation were performed as described in Figure 3A with MDA231-S1a cells expressing indicated shRNAs. CD45 staining was
performed on recipient tumors 19 days after the injection.
(J) Quantification of CD45-positive cells in tumors seeded by MDA231-S1a control and CXCL1 knockdown cells. n = 9.
Error bars in all cases represent SEM and p values were based on two-tailed Mann-Whitney test unless indicated otherwise.injected LacZ/GFP/luciferase-expressing MDA231-LM2 cells
into the circulation of these mice. As these tumors became
seeded with MDA231-LM2 cells, the rate of tumor growth was
accelerated compared to that of unseeded tumors (Figure 6A).
The increase in the size of seeded tumors was reflected in an
increase in the number of tumor cells and was not due to the
less dense packing of cells (Figures S4A and S4B). Notably,
b-galactosidase staining of histological sections revealed that
the LacZ+ seeder cells represented 7% to 19% of the entire
tumor mass, which could not fully account for the larger size of
these tumors (Figures 6B and 6C and data not shown). Of1322 Cell 139, 1315–1326, December 24, 2009 ª2009 Elsevier Inc.note, the intrinsic proliferation rate of MDA231-LM2 is similar
to that of the parental MDA231 population (Gupta et al., 2007),
and the same applies to the MDA231-S1a and S1b lines (data
not shown). These results argue that a small proportion of infil-
trated MDA231-LM2 cells in a mammary tumor can augment
the growth rate of the overall tumor cell population by paracrine
effects on the stroma.
The presence of seederMDA231-LM2 cells inMDA231 tumors
increased theaverage lengthand theextentof branchingof tumor
capillaries as determined subjectively (Figure 6D) and by quanti-
tative digital imaging analysis of CD31-stained vasculature
(Figure S4C). Moreover, the seeded tumors contained elevated
numbersof infiltrating leukocytes,asdeterminedby immunostain-
ing for the pan-leukocyte marker CD45 (Figure 6E) (Charbonneau
et al., 1988). Further analysis of recruited leukocytes revealed
increased numbers of neutrophils as well as macrophages
(CD68-positive cells) in the seeded tumors (Figures 6F and 6G).
We also investigated stroma recruitment in tumors seeded
with 4T1 cells in a syngeneic mouse mammary tumor model
and A375-BoM2 cells in a melanoma model. FACS analysis of
recipient tumors revealed that GFP+ A375-BoM2 seeder cells
represent about 18%–33% of the cells in seeded tumors
whereas GFP+ 4T1 seeder cells account for 3%–8% (Fig-
ure S5A). Tumors seeded by 4T1 cells showed an increase in
leukocyte recruitment (CD45+), the majority of which were
CD11b+myeloid cells (Figure 6H). Over 70%of theCD11b+ cells
were also stained with F4/80, a pan-macrophage marker (Fig-
ure S5B), which is consistent with previous analysis of stromal
composition of 4T1 tumors (DuPre et al., 2007). Analysis of
tumors seeded by A375-BoM2 revealed a limited but significant
increase in neutrophil recruitment (CD45+ Neut+) (Figure 6H).
To provide proof of principle that seeding cells can affect their
host tumor through the release of specific leukocyte-recruiting
signals, we turned our attention to the MDA231 model system
and the seeder-derived chemokine CXCL1, which is a mediator
of leukocyte influx into sites of inflammation (Galkina and Ley,
2007). Unlike the knockdown of MMP1 and FSCN1 expression,
the knockdown of CXCL1 did not diminish the trans-endothelial
migration of MDA231 cells (refer to Figure 5E) or the extent of
seeding of MDA231 tumors with GFP+ MDA231-S1a cells (Fig-
ure 6I). However, CXCL1 knockdown in MDA231-S1a cells
caused a significant decrease in the recruitment of CD45+ cells
into the stroma of seeded MDA231 tumors (Figures 6I and 6J).
These results are consistent with the expected consequences
of an enrichment of a tumor mass with aggressive cancer cells
that secrete stroma-recruiting signals.
DISCUSSION
Based on previous considerations (Norton and Massague,
2006), here we present evidence that tumor self-seeding is a
general phenomenon in experimental models of breast carci-
noma, colon carcinoma, and malignant melanoma. In these
models, tumor masses become readily seeded by CTCs derived
from a separate tumor mass, from metastatic lesions, or from
direct inoculation. We observed self-seeding with homotypic
models using the same cancer cell population as the recipient
tumor mass, and with heterotypic models using cell lines from
different patients and different breast cancer subtypes. Although
our focus is on seeding of a tumor by its own circulating progeny,
we also observed cross-seeding between mammary and mela-
noma tumors (our unpublished results).
The features of tumor self-seeding indicate a process in which
CTCs reinfiltrate a tumor mass based on distinct biological func-
tions, a process that may foster tumor growth and the breeding
of metastatic progenies. Unlike colonization of distant organs,
self-seeding requires little, if any, additional adaptation of
CTCs to the recipient microenvironment. However, self-seeding
does select for cancer cell populations that are more aggressiveCthan the bulk population of the primary tumor. As CTCs, the
seeds have undergone selection for movement into and survival
in the circulation. Moreover, self-seeding is actively driven by the
ability of CTCs to sense attraction signals from the tumor and to
extravasate in response to such signals. These functions are rep-
resented in the most aggressive segment of a CTC population,
including CTCs that may have already acquired a full comple-
ment of metastatic functions.
Tumor self-seeding selects for highly aggressive CTCs, as
shown by our consistent observation that metastatic cell
subpopulations are more efficient as seeders than their parental
populations. Moreover, MDA231 seeder populations recovered
from mammary tumors are a mixed population with a gene
expression profile and a multi-organ metastatic phenotype that
recapitulate those of various site-selective metastatic entities
present in the MDA231 cell population. Bone-, lung-, or brain-
metastatic subpopulations that can be segregated from each
other in experiments of organ-specific metastases (Bos et al.,
2009; Kang et al., 2003; Minn et al., 2005a) emerged as a mixed
population when we selected for tumor-seeding cells. If seeding
selects for highly aggressive segments of a CTC population, then
seeding may foster the expansion of potentially metastatic pop-
ulations in the compatible soil of the primary tumor.
Tumor self-seeding in mice carrying a large load of CTCs was
not accompanied with de novo tumor formation in orthotopic
sites (mammary glands or skin), suggesting that self-seeding
requires tumor-derived attraction signals. Our evidence points
at IL-6 and IL-8 as tumor-derived attractants of CTCs in breast
carcinoma andmelanomamodels. IL-6 and IL-8 have been impli-
cated in several tumorigenic processes including cancer cell
chemoattraction (Arihiro et al., 2000; Wang et al., 1990; Waugh
and Wilson, 2008). High serum levels of IL-6 indicate poor prog-
nosis in breast, colon, and lung cancer (Esfandi et al., 2006;
Knupfer and Preiss, 2007; Schafer and Brugge, 2007), and high
expression of IL-8 in metastatic melanoma is associated with
tumor load (Scheibenbogen et al., 1995; Ugurel et al., 2001).
Inflammatory cells recruited to the tumor site can also be sources
of IL-6 (Balkwill et al., 2005; Grivennikov et al., 2009). Thus,
stroma-derived and cancer cell-derived factors may function in
combination to attract CTCs back to a primary tumor.
Thesuperiorabilityofaggressivecancercells to infiltratea tumor
in response to thisattractionargues that self-seedingalso requires
infiltration functions on the part of the CTCs.We show thatMMP1
and fascin-1 expressed by breast cancer cells act asmediators of
trans-endothelial migration and tumor seeding. Expression of
MMP1 and FSCN1 in estrogen receptor-negative (ER) breast
tumors is associated with relapse to lungs and brain (Bos et al.,
2009;Minn et al., 2005a). Our present and previous results (Gupta
et al., 2007) are consistent with roles of MMP1 and fascin-1 in
cancer cell extravasation—extravasation into distant organs for
the development of metastases but also, as our present results
suggest, extravasation into the tumor of origin.
Themediators of seed attraction and tumor infiltration involved
in self-seeding may well be different depending on the tumor
type. For example, although IL-6 secretion occurs in ER breast
cancer cells, no IL-6 expression is detected in various ER+
breast cancer cell lines (Sasser et al., 2007) or in A375 mela-
noma. Similarly, MMP1 and FSCN1 expression is associatedell 139, 1315–1326, December 24, 2009 ª2009 Elsevier Inc. 1323
with distant relapse in patients with ER breast cancer but not
with ER+ breast cancer (Minn et al., 2005a, 2007). In principle,
seed-attracting signals could include chemoattractants secreted
by tumor cells and/or by inflammatory cells, and tumor infiltration
could involve any mediator of extravasation expressed in CTCs.
The interaction of aggressive cancer cells with the tumor
stroma results in the release of signals that foster tumor growth,
angiogenesis, invasion, and metastasis. These signals promi-
nently include factors that recruit and activate inflammatory
cells. Therefore, to the extent that tumor self-seeding recaptures
highly aggressive segments of a CTC population it may result in
a further enhancement of tumor growth through the action of
seed-derived signals. Indeed, the seeding pattern of recipient
tumors in our experiments was typically uneven and diffuse,
with the seeding cells remaining aminority that mingledwith resi-
dent cancer cells and tumor stroma. The seeding cells did not
have an intrinsic proliferative advantage over the bulk popula-
tion. Yet, seeded MDA231 mammary tumors grow faster, an
increase that is not fully explained by the added mass of the
seeder cells. Enhanced angiogenesis and increased recruitment
of neutrophils andmacrophages accompanied the seeded areas
of these tumors, and seeder-derived CXCL1, which is another
marker of poor prognosis in ER breast cancer (Minn et al.,
2005a, 2007), was partly responsible for this recruitment.
It would be premature to conclude at present that enhanced
tumor growth is an obligate outcome of tumor self-seeding.
The net effect of self-seeding would likely depend on variables
such as the ratio of the tumor size to the size of the CTC popula-
tion, the aggressiveness of the CTCs, the vascularity of the
tumor, tumor microarchitecture, and other factors that may
change in the course of the disease. Self-seeding may provide
harbor in a primary tumor for the expansion of cancer cell
subpopulations that are primed for metastasis. As the shedding
and attraction of CTCs by a tumor mass is a dynamic process, it
is also conceivable that the presence of a substantial tumor
mass could transiently decrease the load of aggressive cells in
the circulation owing to their recapture by the tumor.
The present evidence provides clues that could elucidate
certain enigmas in clinical oncology. The long-established asso-
ciation of large primary tumor size with poor prognosis in many
types of cancer, thought to reflect the ability of larger cancers
to release more cells of metastatic potential, may in addition
reflect the ability of such aggressive cells to self-seed, promoting
local-regional growth, acting in turn as a locus of expansion of
these cells and priming for distant metastases. Similarly, the
association of anaplasia with poor prognosis may be because
micro-anatomical disorganization is a consequence of—and
hence a marker of—assertive self-seeding. The hypervascularity
of many cancers—and the association of such hypervascularity
with poor prognosis—may similarly be explained. Our observa-
tion that a mammary tumor can be seeded by CTCs derived
from lung-metastatic nodules raises the possibility of reseeding
after tumor excision as a potential cause of eventual local recur-
rence. Moreover, that the phenomenon of self-seeding is hereby
linked to tumor-specific and circulating cell-specific factors may
create opportunities for the development of targeted therapies
for the attrition of residual neoplastic cells from the breast and
other organs.1324 Cell 139, 1315–1326, December 24, 2009 ª2009 Elsevier Inc.EXPERIMENTAL PROCEDURES
Additional methods can be found in the Supplemental Data.
Animal Studies
All animal work was done in accordance with a protocol approved by the
MSKCC Institutional Animal Care and Use Committee. Xenografts were per-
formed on BALB/c nude, Athymic nu/nu (for reseeding experiments from the
circulation) and NOD/SCID mice (for contralateral seeding experiments)
were age-matched between 5–8 weeks. Wild-type BALB/c mice were used
for studies in syngeneic model. For contralateral seeding experiments, typi-
cally 5 3 105 unlabeled and GFP/luciferse/TK-expressing tumor cells, unless
noted, were resuspended in a 1:1 mixture of PBS and growth-factor-reduced
Matrigel (BD Biosciences) and injected into contralateral No. 2 mammary
glands (MDA231) or into flanks of NOD/SCIDmice (A375 and SW 620) in a total
volume of 50 ml. At necropsy, recipient tumors were extracted and imaged for
luminescent signals with a Xenogen IVIS system. For experiments with
CN34.BrM2, mice were intraperitoneally injected with etoposide (30 mg/kg
dissolved in DMSO, Sigma) 2 days prior to mammary gland injection. For re-
seeding experiments from the circulation, 2.5 3 105 and 5 3 105 unlabeled
parental MDA231, 67NR, and A375 cells were injected into a mammary gland
No.2 or subcutaneously, respectively. Once the tumors became palpable
(50–100 mm3), 1 3 105 GFP/luiferase-expressing MDA231-LM2, 4T1, or
A375-BoM2 cells were injected into the cardiac left ventricle in a total volume
of 100 ml. Reseeding was monitored by BLI. Recipient tumors were extracted
and imaged at the necropsy, typically 6–7 weeks after mammary gland injec-
tion. MMTV-PyMT transgenic mice in which mammary tumors are developed
by the MMTV promoter-driven expression of the polyoma middle-T oncogene
were used for reseeding experiment from the circulation. Cells derived from
one such tumor were transduced with lentivirus encoding GFP/luciferase/TK
and used for intracardiac injection. Tumors were harvested and imaged after
3 weeks. For reseeding from lung metastases, 2 3 105 MDA231-LM2 cells
were injected into the lateral tail vein. After 3 weeks, 53 105 unlabeled parental
MDA-MB-231 cells were injected into a mammary gland No. 2. After 3–4
weeks, tumors were extracted and imaged. Relative numbers of CTC from
these mice were analyzed as previously described (Gupta et al., 2007) except
that primers against luciferase were used to detect CTCs. Experimental
metastasis assays and calculation of tumor size were done as previously
described (Bos et al., 2009; Kang et al., 2003; Minn et al., 2005a).
In Vivo Selection of Seeder Cells
One million unlabeled and GFP/luciferase/TK-expressing parental MDA-MB-
231 or A375 cells were injected as in contralateral seeding experiments. Fifty
days after the injection, recipient tumors were extracted and imaged by BLI as
previously described (Minn et al., 2005a). Two independent seeded tumors by
MDA-MB-231 cells and one seeded tumor by A375 cells were minced and
centrifuged in PBS-containing antibiotics. Samples were then resuspended
in DMEM containing 0.125% collagenase III and 0.1% of hyaluronidase and
incubated at 37C for 2.5 hr with occasional trituration. Subsequently, samples
were trypsinized for 5 min, followed by centrifugation in DMEMwith 10% FBS.
Cells were filtered through a 40 mm strainer and plated in a T75 flask with
DMEM containing 10% FBS. Cells were expanded in culture for two passages
and GFP-positive cells were isolated by FACS.
Trans-Well Migration Assays
To generate conditioned media, 106 cells were plated on a 6 cm dish. The next
day media were replaced with 0.2% FBS media without growth factors. After
2 days, media were collected, centrifugated, and used in trans-well migration
assays as described previously (Gupta et al., 2007). Recombinant human IL-6
and IL-8 were purchased from R&D systems.
Cytokine Antibody Array
Cytokine antibody arraywas performedwith conditionedmedia fromMCF10A,
MDA231, MDA231-S1a, MDA231-S1b, MDA231-LM2, MCF7, HaCat, A375,
and A375-BoM2 according to manufacturer’s protocol. The complete array
maps (Array 5, 9, and 10) can be found at http://www.raybiotech.com/
map_all_m.asp#8.
Statistical Analysis
For trans-well migration assays and animal studies in which a value is quanti-
fied relative to a normalized standard, standard deviation was calculated
based on the following formula:
sdff=gg= ðf=gÞ
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
sdffg2=f2+ ½sdfgg2=g2
q
where f and g represent the mean of experimental and control data points,
respectively. sd, standard deviation. Standard error of the mean (SEM) was
then calculated by using sd{f/g} /O n.
ACCESSION NUMBERS
Gene expression data of MDA231-S1 cells are deposited at GEO (GSE18833).
SUPPLEMENTAL DATA
Supplemental Data include five figures, one table, and Supplemental Experi-
mental Procedures and can be found with this article online at http://www.
cell.com/supplemental/S0092-8674(09)01437-8.
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